Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

116.27 3.02 +2.67%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
58.4×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

30.39% 29.87% 30.82% 30.67%
Piotroski F-Score
8 9 8 6
ROA
20.96% 20.75% 21.88% 23.55%
ROIC
52.81% 58.55% 61.52% 60.50%
Return on Tangible Assets
31.80% 30.35% 30.37% 29.73%
Average Days of Receivables
67.94 72.73 71.59 70.57
Free Cash Flow per Share
5.99 6.81 7.13 9.43
Free Cash Flow
1,172.04 1,329.63 1,420.88 1,890.47
Other line items

Show all line items

Columns are period end dates